Xue Xiaoxia, Wang Xiangpeng, Pang Mingshi, Yu Liuchunyang, Qian Jinxiu, Li Xiaoyu, Tian Meng, Lu Cheng, Xiao Cheng, Liu Yuanyan
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
J Nanobiotechnology. 2024 Apr 21;22(1):196. doi: 10.1186/s12951-024-02452-1.
Tumors desmoplastic microenvironments are characterized by abundant stromal cells and extracellular matrix (ECM) deposition. Cancer-associated fibroblasts (CAFs), as the most abundant of all stromal cells, play significant role in mediating microenvironments, which not only remodel ECM to establish unique pathological barriers to hinder drug delivery in desmoplastic tumors, but also talk with immune cells and cancer cells to promote immunosuppression and cancer stem cells-mediated drug resistance. Thus, CAFs mediated desmoplastic microenvironments will be emerging as promising strategy to treat desmoplastic tumors. However, due to the complexity of microenvironments and the heterogeneity of CAFs in such tumors, an effective deliver system should be fully considered when designing the strategy of targeting CAFs mediated microenvironments. Engineered exosomes own powerful intercellular communication, cargoes delivery, penetration and targeted property of desired sites, which endow them with powerful theranostic potential in desmoplastic tumors. Here, we illustrate the significance of CAFs in tumors desmoplastic microenvironments and the theranostic potential of engineered exosomes targeting CAFs mediated desmoplastic microenvironments in next generation personalized nano-drugs development.
促结缔组织增生性微环境肿瘤的特征是有丰富的基质细胞和细胞外基质(ECM)沉积。癌症相关成纤维细胞(CAFs)作为所有基质细胞中数量最多的细胞,在介导微环境中发挥着重要作用,它不仅重塑ECM以建立独特的病理屏障来阻碍促结缔组织增生性肿瘤中的药物递送,还与免疫细胞和癌细胞相互作用以促进免疫抑制和癌症干细胞介导的耐药性。因此,CAFs介导的促结缔组织增生性微环境将成为治疗促结缔组织增生性肿瘤的有前景的策略。然而,由于此类肿瘤中微环境的复杂性和CAFs的异质性,在设计靶向CAFs介导的微环境的策略时应充分考虑有效的递送系统。工程化外泌体具有强大的细胞间通讯、货物递送、穿透和靶向所需位点的特性,这赋予它们在促结缔组织增生性肿瘤中强大的诊疗潜力。在此,我们阐述了CAFs在肿瘤促结缔组织增生性微环境中的重要性以及工程化外泌体在下一代个性化纳米药物开发中靶向CAFs介导的促结缔组织增生性微环境的诊疗潜力。